Secondary acute promyelocytic leukemia following chemotherapy for non-Hodgkin's lymphoma in a child

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 7, 2004, Pages 427-430

  Ogami, Aya ^a   Morimoto, Akira ^a   Hibi, Shigeyoshi ^a   Todo, Shinjiro ^a   Sugimoto, Tohru ^a   Mori, Kanako ^b   Imamura, Toshihiko ^b   Ishida, Hiroyuki ^b   Yoshihara, Takao ^b   Iguchi, Akihiro ^c   Imaizumi, Masue ^d   Imashuku, Shinsaku ^e  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^c Kitami Red Cross Hospital   (Japan)

^d MIYAGI CHILDREN S HOSPITAL   (Japan)

^e Kyoto City Institute of Health and Environmental Sciences   (Japan)

Author keywords

Acute promyelocytic leukemia; Doxorubicin; Hematopoietic stem cell transplantation; Therapy related leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID; VINCRISTINE;

ARTICLE; CANCER REGRESSION; CASE REPORT; CHILD; CHILDHOOD CANCER; DISEASE ASSOCIATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTIOCYTOSIS X; HLA MATCHING; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RARE DISEASE; SECOND CANCER;

ANTINEOPLASTIC AGENTS; BONE MARROW; BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; NEOPLASMS, SECOND PRIMARY; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; TRANSLOCATION, GENETIC;

EID: 3543134884     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200407000-00005     Document Type: Article

References (18)

1. Leone G, Voso MT, Sica S, et al. Therapy related leukemias: susceptibility, prevention and treatment. Leukemia Lymphoma. 2001;41:255-276.
2. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21:2123-2137.
3. Haupt R, Fears TR, Rosso P, et al. Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis. Pediatr Hematol Oncol. 1994;11:499-507.
4. Haupt R, Fears TR, Heise A, et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations. Int J Cancer. 1997;71:9-13.
5. Suzuki H, Imaizumi M, Sato A, et al. Monitoring of minimal residual disease in children with acute promyelocytic leukemia by RT-PCR detecting PML/RARalpha chimeric gene: a retrospective study of clinical feasibility. Tohoku J Exp Med. 2001;193:123-139.
6. Egeler RM, Neglia JP, Arico M, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am. 1998;12:369-378.
7. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood. 2002;100:1972-1976.
8. Andersen MK, Larson RA, Mauritzson N, et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:395-400.
9. Detourmignies L, Castaigne S, Stoppa AM, et al. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol. 1992;10:1430-1435.
10. Ariyoshi N, Kamizono A, Shirahata S. A case of identical twins with Langerhans cell histiocytosis developing acute promyelocytic leukemia during chemotherapy. Jpn J Pediatr Hematol. 1994;8:317.
11. Arico M, Comelli A, Bossi G, et al. Langerhans cell histiocytosis and leukemia: unusual association in two cases. Med Pediatr Oncol. 1993;21:271-273.
12. Horibe K, Matsushita T, Numata S, et al. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis. Cancer. 1993;72:3723-3726.
13. Matsuzaki A, Inamitsu T, Watanabe T, et al. Acute promyelocytic leukemia in a patient treated with etoposide for Langerhans cell histiocytosis. Br J Haematol. 1994;86:887-889.
14. Lopez-Andrew JA, Ferris J, Verdeguer A, et al. Secondary acute promyelocytic leukemia in a child treated with epipodophyllotoxins. Am J Pediatr Hematol Oncol. 1994;16:384-386.
15. Lopes LF, de Camargo B. Secondary acute promyelocytic leukemia after treatment with etoposide for Langerhans cell histiocytosis (LCH). Med Pediatr Oncol. 1999;32:315.
16. Dufour C, Lanciotti M, Micalizzi C, et al. Non-identical twin sisters concordant for Langerhans cell histiocytosis and discordant for secondary acute promyelocytic leukemia. Med Pediatr Oncol. 2001;37:70-72.
17. Schiavetti A, Varrasso G, Maurizi P, et al. Ten-day schedule oral etoposide therapy in advanced childhood malignancies. J Pediatr Hematol Oncol. 2000;22:119-124.
18. Imashuku S, Teramura T, Kuriyama K, et al. Risk of Etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Int J Hematol. 2002;75:174-177.